{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:26:45Z","timestamp":1786649205924,"version":"build-2736575974"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,13]]},"DOI":"10.7759\/cureus.114492","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:28:03Z","timestamp":1786645683000},"source":"Crossref","is-referenced-by-count":0,"title":["Recognizing Euglycemic Diabetic Ketoacidosis in the Era of SGLT2 Inhibitors: A Case Report"],"prefix":"10.7759","author":[{"given":"Jose  C","family":"Serrano Reyes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria F","family":"Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolando  L","family":"Jaen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid J","family":"Batista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-S016","article-title":"16. Diabetes care in the hospital: standards of care in diabetes-2026","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes. 16. Diabetes care in the hospital: standards of care in diabetes-2026. Diabetes Care. 2026, 49:S339-55. 10.2337\/dc26-S016","journal-title":"Diabetes Care"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2023-003666","article-title":"Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors","volume":"11","author":"Chow E","year":"2023","unstructured":"Chow E, Clement S, Garg R. Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors. BMJ Open Diabetes Res Care. 2023, 11:003666. 10.1136\/bmjdrc-2023-003666","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Peters AL","year":"2015","unstructured":"Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015, 38:1687-93. 10.2337\/dc15-0843","journal-title":"Diabetes Care"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2019.03.014","article-title":"Euglycemic diabetic ketoacidosis","volume":"63","author":"Barski L","year":"2019","unstructured":"Barski L, Eshkoli T, Brandstaetter E, Jotkowitz A. Euglycemic diabetic ketoacidosis. Eur J Intern Med. 2019, 63:9-14. 10.1016\/j.ejim.2019.03.014","journal-title":"Eur J Intern Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2016.15","article-title":"Diabetic emergencies-ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia","volume":"12","author":"Umpierrez G","year":"2016","unstructured":"Umpierrez G, Korytkowski M. Diabetic emergencies-ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nat Rev Endocrinol. 2016, 12:222-32. 10.1038\/nrendo.2016.15","journal-title":"Nat Rev Endocrinol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1380","article-title":"Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors","volume":"38","author":"Rosenstock J","year":"2015","unstructured":"Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015, 38:1638-42. 10.2337\/dc15-1380","journal-title":"Diabetes Care"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-024-09073-2","article-title":"Euglycemic ketoacidosis associated with SGLT-2 inhibitors in non-diabetic patients: a narrative review","volume":"40","author":"Garg R","year":"2025","unstructured":"Garg R, Sood N, Bansal O, Hoskote A. Euglycemic ketoacidosis associated with SGLT-2 inhibitors in non-diabetic patients: a narrative review. J Gen Intern Med. 2025, 40:437-42. 10.1007\/s11606-024-09073-2","journal-title":"J Gen Intern Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-9032","article-title":"Hyperglycemic crises in adult patients with diabetes","volume":"32","author":"Kitabchi AE","year":"2009","unstructured":"Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009, 32:1335-43. 10.2337\/dc09-9032","journal-title":"Diabetes Care"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2174\/1573399812666160421121307","article-title":"Euglycemic diabetic ketoacidosis: a review","volume":"13","author":"Modi A","year":"2017","unstructured":"Modi A, Agrawal A, Morgan F. Euglycemic diabetic ketoacidosis: a review. Curr Diabetes Rev. 2017, 13:315-21. 10.2174\/1573399812666160421121307","journal-title":"Curr Diabetes Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2021.02.015","article-title":"Euglycemic diabetic ketoacidosis: etiologies, evaluation, and management","volume":"44","author":"Long B","year":"2021","unstructured":"Long B, Lentz S, Koyfman A, Gottlieb M. Euglycemic diabetic ketoacidosis: etiologies, evaluation, and management. Am J Emerg Med. 2021, 44:157-60. 10.1016\/j.ajem.2021.02.015","journal-title":"Am J Emerg Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2019.12.006","article-title":"SGLT2 inhibitor-induced euglycemic diabetic ketoacidosis: a case report","volume":"2","author":"Wang KM","year":"2020","unstructured":"Wang KM, Isom RT. SGLT2 inhibitor-induced euglycemic diabetic ketoacidosis: a case report. Kidney Med. 2020, 2:218-21. 10.1016\/j.xkme.2019.12.006","journal-title":"Kidney Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S1262-3636(14)72693-X","article-title":"Adverse effects and safety of SGLT-2 inhibitors","volume":"40","author":"Halimi S","year":"2014","unstructured":"Halimi S, Verg\u00e8s B. Adverse effects and safety of SGLT-2 inhibitors. Diabetes Metab. 2014, 40:S28-34. 10.1016\/S1262-3636(14)72693-X","journal-title":"Diabetes Metab"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/504642-recognizing-euglycemic-diabetic-ketoacidosis-in-the-era-of-sglt2-inhibitors-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:28:04Z","timestamp":1786645684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/504642-recognizing-euglycemic-diabetic-ketoacidosis-in-the-era-of-sglt2-inhibitors-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.114492","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,13]]}}}